FDA Announces Public Meeting of Cellular, Tissue, and Gene Therapies Advisory Committee to Discuss Sarepta Therapeutics' BLA for Duchenne Muscular Dystrophy Treatment

Summary

The FDA is hosting a public meeting of its Cellular, Tissue, and Gene Therapies Advisory Committee to discuss a Biologics License Application (BLA) from Sarepta Therapeutics, Inc. for a treatment of Duchenne muscular dystrophy (DMD) in ambulatory patients.